This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Agonists Endothelin 1 Endothelin 2 Endothelin 3 IRL-1620 Sarafotoxin Antagonists A-192621 Ambrisentan Aprocitentan Atrasentan Avosentan Bosentan BQ-123 BQ-788 Clazosentan Darusentan Edonentan Enrasentan Fandosentan Feloprentan Macitentan Nebentan Sitaxentan Sparsentan Tezosentan Zibotentan
== Pharmacokinetics == Synthetic cannabinoids are delivered by smoking. In a human study, after 50 μg/kg smoked JWH-018 are delivered, one male and a female have their serum concentration of 8.1 and 10.2 μg/L respectively after 5 minutes, down to 4.6 and 6.1 μg/L after 15 minutes, suggesting the biological half-life of JWH-018 is short. 13 phase 1 metabolites are identified. Monohydroxylated and dihydrodiol metabolites are most prevalent metabolites of synthetic cannabinoids. UGT1A1, UGT1A3, UGT1A9, UGT1A10 and UGT2B7 isoenzymes were primarily responsible for JWH-018 and JWH-073 metabolites' conjugation and had high affinity for hydroxylated metabolites (Km=12–18 mmol/L). Generation of JWH-018-N-4- and 5-hydroxypentyl (JWH-018 metabolites) was primarily mediated by CYP2C9 followed by CYP1A2 and CYP2C19. CYP3A4 catalyzed JWH-018-N-4-hydroxypentyl production but with lower activity than CYP1A2 and CP2C19. The drugs are mainly excreted as urine. Phenethylamines are first-order kinetics with half life of 5 to 10 minutes which are absorbed by ingestion. The drugs have low concentration in the brain due to low biological half-life. It is difficult to measure the plasma concentration due to low stability of Phenethylamine. There are two possible metabolism pathways. The first possible pathway is metabolism by MAO-B (an intracellular enzyme mainly in the brain and tightly bound to the outer membrane of mitochondria which deaminates free primary and secondary amines) to form phenylacetic acid due to MAO-B selectivity on non-polar aromatic amines.
=== Mass spectrometry === Biochemical approaches such as Western blotting may provide supporting evidence that a protein is modified by O-GlcNAc; mass spectrometry (MS) is able to provide definitive evidence as to the presence of O-GlcNAc. Glycoproteomic studies applying MS have contributed to the identification of proteins modified by O-GlcNAc. As O-GlcNAc is substoichiometric and ion suppression occurs in the presence of unmodified peptides, an enrichment step is usually performed prior to mass spectrometry analysis. This may be accomplished using lectins, antibodies, or chemical tagging. The O-GlcNAc modification is labile under collision-induced fragmentation methods such as collision-induced dissociation (CID) and higher-energy collisional dissociation (HCD), so these methods in isolation are not readily applicable for O-GlcNAc site mapping. HCD generates fragment ions characteristic of N-acetylhexosamines that can be used to determine O-GlcNAcylation status. In order to facilitate site mapping with HCD, β-elimination followed by Michael addition with dithiothreitol (BEMAD) may be used to convert the labile O-GlcNAc modification into a more stable mass tag. For BEMAD mapping of O-GlcNAc, the sample must be treated with phosphatatase otherwise other serine/threonine post-translational modifications such as phosphorylation may be detected. Electron-transfer dissociation (ETD) is used for site mapping as ETD causes peptide backbone cleavage while leaving post-translational modifications such as O-GlcNAc intact.
Sources: en.wikipedia.org
Sinn Féin endorse Catherine Connolly in the 2025 Irish presidential election. 21 September – The UK announces its formal recognition of Palestine as a sovereign state. Former MP Callum McCaig is appointed chief executive of the Scottish National Party. 22 September – Chancellor Rachel Reeves accuses "hostile states like Russia" of being behind a series of recent cyberattacks in the UK. Reform UK announces it will abolish the right of migrants to qualify for permanent settlement in the UK after five years if it wins the next election. SNP councillor Grant Laing, resigns as leader of Perth and Kinross Council after he is charged with embezzlement. 23 September – Ed Davey gives his keynote speech to the 2025 Liberal Democrats Party Conference. Former Scottish Government minister Jamie Hepburn apologises to Holyrood for his conduct. 24 September – Bridget Phillipson says she has been the victim of sexist briefings amid the 2025 Labour Party deputy leadership election. Jeremy Corbyn apologises for the confusion surrounding the launch of Your Party. 25 September – Andy Burnham is rebuked by some Labour MPs around his potential leadership bid. Steph Driver resigns as Downing Street Director of Communications. Ministers consider supporting Jaguar Land Rover suppliers whilst car production is suspended due to a cyber-attack. 26 September – John McDonnell and Apsana Begum are readmitted to the Labour Party following their suspension in 2024 over a vote against the government on the two-child benefit cap. 27 September – The 2025 Labour Party Conference begins in Liverpool.
==== Maryland Blue Ribbon Schools ==== Beacon Heights Elementary School, Riverdale, 2003–04 Bond Mill Elementary School, Laurel (year N/A) Columbia Park Elementary School, Landover, 1987–88 Fort Foote Elementary School, Fort Washington, 2000–01 Glenarden Woods Elementary School, Glenarden, 2005–06 Greenbelt Center Elementary School, Greenbelt, 1991–92 Heather Hills Elementary School, Bowie, 1989–90 & 2006–07 Rockledge Elementary School, Bowie, 1997–98 Whitehall Elementary School, Bowie, 2011–12 Templeton Elementary School, Riverdale, 1998–99 Kenmoor Middle School, Landover, 1988–89 Dora Kennedy French Immersion, Greenbelt, 2013–14 Kettering Middle School, Upper Marlboro, 1992–93 Martin Luther King, Jr. Middle School, Beltsville, 1992–93 Eleanor Roosevelt High School, Greenbelt, 1990–91 & 1997–98 Suitland High School, Forestville, 1988–89
Treacher Collins syndrome (TCS) is a genetic disorder characterized by deformities of the ears, eyes, cheekbones, and chin. The degree to which a person is affected may vary from mild to severe. Complications may include breathing problems, vision problems, cleft palate, and hearing loss. Those affected generally have normal intelligence. TCS is usually autosomal dominant. More than half of occurrences are as a result of a new mutation rather than inherited. The involved genes may include TCOF1, POLR1C, or POLR1D. Diagnosis is generally based on symptoms and X-rays, and potentially confirmation by genetic testing. Treacher Collins syndrome is not curable. Symptoms may be managed with reconstructive surgery, hearing aids, speech therapy, and other assistive devices. Life expectancy is generally normal. TCS occurs in about one in 50,000 people. The syndrome is named after Edward Treacher Collins, an English surgeon and ophthalmologist, who described its essential traits in 1900.
Sources: en.wikipedia.org
Free Fluid Mechanics books Annual Review of Fluid Mechanics. Archived 2009-01-19 at the Wayback Machine. CFDWiki – the Computational Fluid Dynamics reference wiki. Educational Particle Image Velocimetry Archived 2017-08-03 at the Wayback Machine – resources and demonstrations
In Lao cuisine, Lao coriander is used extensively in traditional Lao dishes such as 'mok pa' (steamed fish in banana leaf) and several coconut milk curries that contain fish or prawns. In China dill is called colloquially, 'huíxiāng' (茴香, perfume of Hui people), or more properly 'shíluó' (莳萝/蒔蘿). It is a common filling in 'baozi', 'jiaozi' and 'xianbing' and may be used as vegetarian with rice vermicelli, or combined with either meat or eggs. Vegetarian dill baozi are a common part of a Beijing breakfast. In baozi and xianbing, it often is interchangeable with non-bulbing fennel and the term 茴香 also may refer to fennel, similarly to caraway and coriander leaf, sharing a name in Chinese as well. Dill also may be stir fried as a potherb, often with egg, in the same manner as Chinese chives. In Northern China, Beijing, Inner-Mongolia, Ningxia, Gansu, and Xinjiang, dill seeds commonly are called 'zīrán' (孜然), but also 'kūmíng' (枯茗), 'kūmíngzi' (枯茗子), 'shíluózi' (莳萝子/蒔蘿子), 'xiǎohuíxiāngzi' (小茴香子) and are used with pepper for lamb meat. In the whole of China, 'yángchuàn' (羊串) or 'yángròu chuàn' (羊肉串), lamb brochette, a speciality from Uyghurs, uses cumin and pepper. In Cantonese-speaking regions such as Hong Kong and Macau, the leaves are more colloquially known as 刁草 (diu1 cou2), a partial calque of the English 'dillweed'; 'dill' transliterated into the otherwise unrelated 刁 diu1 and 'weed' translated as 草 cou2. In Taiwan, it is also commonly used as a filling in steamed buns (baozi) and dumplings (jiaozi). In Vietnam, the use of dill in cooking is regional.
=== Cooking === Some culinary uses of syringes are injecting liquids (such as gravy) into other foods, or for the manufacture of some candies. Syringes may also be used when cooking meat to enhance flavor and texture by injecting juices inside the meat, and in baking to inject filling inside a pastry. It is common for these syringes to be made of stainless steel components, including the barrel. Such facilitates easy disassembly and cleaning.
A number of natural toxins that interfere with actin's dynamics are widely used in research to study actin's role in biology. Latrunculin – a toxin produced by sponges – binds to G-actin preventing it from joining microfilaments. Cytochalasin D – produced by certain fungi – serves as a capping factor, binding to the (+) end of a filament and preventing further addition of actin molecules. In contrast, the sponge toxin jasplakinolide promotes the nucleation of new actin filaments by binding and stabilizing pairs of actin molecules. Phalloidin – from the "death cap" mushroom Amanita phalloides – binds to adjacent actin molecules within the F-actin filament, stabilizing the filament and preventing its depolymerization. Phalloidin is often labelled with fluorescent dyes to visualize actin filaments by fluorescence microscopy.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.